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Abstract
Background: Consensus Conferences and Guidelines for deep vein thrombosis prophylaxis have
been published, which recommend the use of prophylactic heparins in patients with risk of venous
thromboembolism (VTE). The aim of this study was the assessment of the prophylaxis of VTE and
the adherence to accepted guideline recommendations throughout the hospital.
Methods: A cross-sectional study was carried out in a teaching hospital after guidelines were
implemented. Patients' risk factors of deep vein thrombosis, risk categories of patients, and
prophylaxis used in different wards were recorded. Appropriate adherence to the guidelines was
analysed.
Results: Of 397 patients, prophylaxis was used in 231 patients (58%), and low-molecular-weight
heparins (LMWH) were used in 224 of them (97%). Patients with prophylaxis had a higher mean
number of risk factors (SD) than those without prophylaxis [3.1 (1.4) vs 1.9 (1.4); p < 0.05)].
Prophylaxis was used in 72% and 90% of moderate and high-risk patients respectively. Appropriate
adherence to all guideline recommendations was observed in 42% of patients. Adherence to
guidelines was high as regards the use of prophylaxis according to patients' risk factors (78%) and
the use of appropriate types of prophylaxis (99%), but was low regarding appropriate heparin
dosage (47%) and preoperative dosage (37%). Appropriate prophylaxis use was higher in critical
care and surgical wards than in medical wards.
Conclusion: Prophylaxis of VTE is generally used in risk patients, but appropriate adherence to
guidelines is less frequent and variable among different wards. Continuing medical education,
discussion and dissemination of guidelines, and regular clinical audit are necessary to improve
prophylaxis of VTE in clinical practice.
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Background
Several clinical trials and meta-analysis have showed effi-
cacy and safety of prophylaxis with non-fractionated and
fractionated heparins for preventing VTE [1-10]. In addi-
tion to this, Consensus Conferences and Guidelines for
deep vein thrombosis prophylaxis have been published,
which recommend the use of prophylactic heparins in
patients at risk of venous thrombosis [11-14]. In spite of
this scientific evidence, several studies have shown under-
use of prophylaxis [15-18]. Previous studies carried out in
our hospital on the use of deep vein thrombosis prophy-
laxis showed poor adherence to accepted recommenda-
tions [16,19]. The main problem was low use of
prophylaxis in moderate/high risk patients. Subsequently,
a guideline was elaborated in our institution, based on
mentioned recommendations and disseminated through
multifaceted intervention. Few studies have assessed the
use of the thromboprophylaxis after implementing guide-
lines and differences among different wards in hospitals.
The aims of the study were the assessment of the use of the
prophylaxis of VTE throughout the hospital after imple-
mentation and dissemination of the guideline; and the
assessment of the adherence to recommendations of the
guidelines in the whole hospital and in different wards.
Methods
A cross-sectional study throughout a teaching hospital
was carried out in 1999, four years after the institutional
guideline was disseminated. A working group developed
the guideline for preventing VTE in a two-stage process.
Initially, an ad hoc institutional working group with mem-
bers of the different parties concerned (i.e., haematolo-
gists, clinical pharmacologists, surgeons, other clinical
specialists, and nurses) reviewed current practice as well as
accepted scientific standards, and produced specific
guidelines. The recommendations were based on widely
accepted guidelines (table 1) [11,12]. Afterwards, an
attractive, pocket-size booklet was edited, which was pre-
sented, discussed and distributed to all nurses' shifts and
physicians at specially convened meetings. In addition,
during the following four years the booklet was also dis-
tributed to all junior physicians that were doing postgrad-
uate training programs at the centre.
All patients admitted to the General Area of the hospital
were selected for inclusion in the study. Patients from
Maternity and Paediatric Area, and Traumatology-Ortho-
paedics Area were not included, and therefore children,
obstetrical and gynaecological patients, orthopaedic and
traumatology patients were not included in our study as
such areas are located in different premises and separately
managed in our institution. In addition, patients who
might require anticoagulant treatment for medical rea-
sons (venous thromboembolic disease, peripheral arterial
disease, coronary heart disease, atrial fibrillation and
prosthesic heart valves) were also excluded. Physicians
trained for data extraction reviewed all medical records
and nurse sheets. Information about demographic charac-
teristics of patients, patients' risk factors of deep vein
thrombosis, type of prophylaxis used, contraindications
for using anticoagulants, the ward where the patient was
admitted, and adherence to the guideline's recommenda-
tions were recorded. A specific committee ensured that all
patients were correctly screened before being included in
the study and decided the allocation of the patients to one
of the risk groups. The patient could be admitted to the
following wards: medical wards (internal medicine and
other medical specialities), surgical wards (general surgery
and other surgical specialities), critical care units, and
emergency department. According to guideline recom-
mendations patients were classified in three risk catego-
ries: low, moderate and high, and the risk scoring was a
part of guideline implementation. Recommendations of
guidelines were: a) early physical activity without other
prophylaxis, such as heparins, in low risk patients; b)
prophylaxis with low LMWH dose in moderate risk
patients (or physical measures in patients with contraindi-
cations for the use heparins or acetylsalicylic acid in spe-
cific cases); and c) prophylaxis with higher LMWH dose in
high risk patients (or physical measures in patients with
contraindications for the use of heparins or acetylsalicylic
acid in specific cases).
Appropriate adherence to the guidelines was assessed. The
following indicators of adherence to guideline recom-
mendations were analysed:
1) The proportion of patients receiving appropriate
prophylaxis according to patients' risk category (no
prophylaxis in low-risk patient and prophylaxis in moder-
ate and high-risk patients);
2) The proportion of appropriate types of prophylaxis in
moderate and high-risk patients (heparins in patients
without contraindications and physical measures in
patients with contraindications);
3) The proportion of appropriate dosage of heparins in
moderate (low prophylactic dosage) and high-risk
patients (high prophylactic dosage);
4) The proportion of preoperative dose used in surgical
patients;
Data was analysed with SPSS/PC statistical software pack-
age. Statistical analysis was performed using Pearson χ2
test or test for trends to compare proportions and ANOVA
to compare means. A 5 per cent level of significance was
accepted for all statistical tests.Thrombosis Journal 2004, 2 http://www.thrombosisjournal.com/content/2/1/3
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Results
Of 582 patients admitted to the hospital, 397 patients
were included (figure 1), of which 166 (42%) were hospi-
talised in medical wards, 155 (39%) in surgical wards, 44
(11%) in critical care units, and 32 (8%) in the emergency
department. The mean age (SD) of patients was 60 (17)
years old [median age 64; range 15 – 92] and 229 patients
(58%) were men. The majority of patients had risk factors
of deep vein thrombosis [mean (SD) 2.6 (1.5); median 2,
range 0–8], thus 302 (76%) had two or more risk factors,
and 190 (48%) had three or more. The most frequent risk
factors were age ≥ 40 years (335; 84%), surgery 148
(37%), immobilisation (145; 36.5%), cancer (128; 32%),
obesity (61; 15%) and heart failure (24; 6%). According
to guideline's assessment of risk, 297 patients (75%) were
classified as having moderate or high risk. A relationship
was observed between the number of risk factors and risk
categories according to guidelines on the basis of the
guideline specifications. The mean number of risk factors
(SD) was 1 (0.7) in low-risk patients, 2.9 (1.2) in moder-
ate-risk patients, and 4.1 (1.1) in high risk patients (F =
150.8; p < 0.0001).
Prophylaxis of venous thrombosis was used in 231
patients (58%). Pharmacological prophylaxis with low-
molecular-weight heparins (LMWH) was applied to 224
patients (97%) and with non-fractionated heparin (NFH)
to only one patient (0.5%). Non pharmacological proph-
ylaxis with elastic stockings was utilised in 6 patients
(2.5%). Only 42 patients (11%) had some contraindica-
tion, absolute or relative, concerning the use of heparins
(21 active haemorrhage, 9 conditions that may lead to
bleeding, such as an active peptic ulcer or hepatic injury,
8 haemorrhagic stroke, 2 severe coagulopathy and 2
Table 1: Categories of risk groups for venous thromboembolism in inpatients
Low risk groups Minor surgery (<30 min); no risk factor other than age
Major surgery (>30 min); age < 40 years; no other risk factors1,2
Minor trauma or medical illness
Moderate risk groups Major general, urological, gynaecological, cardiothoracic, vascular, or neurological surgery; age ≥ 40 years or other 
risk factor1,2
Major medical illness: heart or lung disease, cancer, inflammatory bowel disease
Major trauma or burns
Minor surgery, trauma or illness in patients with previous deep vein thrombosis, pulmonary embolism, or 
thrombophilia
High risk groups Fracture or major orthopaedic surgery of pelvis, hip, or lower limb
Major pelvic or abdominal surgery for cancer
Major surgery, trauma, or illness in patients with previous deep vein thrombosis, pulmonary embolism, or 
thrombophilia
Lower limb paralysis (for example, hemiplegic stroke, paraplegia)
Major lower limb amputation
1 Risk factors according to patients factors: age, obesity, immobility (bed rest over 4 days), high dose oestrogen therapy, previous deep vein 
thrombosis or pulmonary embolism, thrombophilia (deficiency of antithrombin III, protein C, or protein S, antiphospholipid antibody or lupus 
anticoagulant) 2 Risk factor according to disease or surgical procedure: trauma or surgery, malignancy (especially pelvic, abdominal, metastasic), 
hearth failure, recent myocardial infarction, paralysis of lower limb(s), infection, inflammatory bowel disease, nephrotic syndrome, polycythaemia, 
paraproteinaemia, paroxysmal nocturnal haemoglobinuria, Behçet's disease, homocystinaemia.
Patients included in the study Figure 1
Patients included in the study
                                     643 beds
                                                            61 beds unoccupied                
                            582 patients hospitalised
Patients not included
           Hospitalisation < 24 hours  (60)
                      Anticoagulation treatment (VTE, IC, PA) (90)
                      Prophylaxis of arterial embolism (AF, HVP)  (8)
Inadequate data    (27) 
                            397 patients (62%) included 
 low-risk patients                moderate and high-risk patients
          100 (25%)                           297 (75%)
VTE Venous Thromboembolism 
IC     Isquemic Cardiopathy 
PA    Peripheric Arteriopathy 
AF    Atrial Fibrillation 
HVP Heart Valve ProsthesisThrombosis Journal 2004, 2 http://www.thrombosisjournal.com/content/2/1/3
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hypersensitivity to heparins). Of 166 patients without
prophylaxis only 31 (19%) had some contraindication for
the use of heparins.
Patients in whom prophylaxis was used had a higher
mean number (SD) of risk factors than patients without
prophylaxis [3.1 (1.4) vs. 1.9 (1.4); p < 0.05)]. The higher
the patients' number of risk factors, the more often proph-
ylaxis was used (table 2). Prophylaxis was used in the
majority of moderate and high-risk patients (71.6% and
90% respectively). Of 77 moderate and high-risk patients
who did not receive prophylaxis, only 14 (18%) had some
contraindication for the use of heparins. Table 3 shows
characteristics of the patients and prophylaxis in different
risk categories established in guidelines. Prophylaxis was
used in 81% (120) of patients undergoing surgery (148),
90% in moderate-risk and 91% in high-risk patients.
Table 4 shows characteristics of patients according to risk
factors and use of prophylaxis of VTE in different wards;
the results varied widely between different wards.
Adherence to all guideline recommendations only was
observed in 167 patients (42%). Figure 2 shows appropri-
ate adherence to guidelines according to patients' risk fac-
tors. Adherence to guidelines was high in relation to the
prophylaxis use (308 of 397 patients; 77.6% appropriate)
and the type of prophylaxis (217 of 220; 98.6 % appropri-
ate), but was low with regard to heparin dosage (101 of
213; 47% appropriate) and preoperative dosage (55 of
148; 37% appropriate). Appropriate prophylaxis use was
higher in surgical (85.2%) and critical care (90.9%) wards
than in emergency (62.5%) and medical (69.9%) wards.
Discussion
The study explores the gap between practice and available
knowledge or evidence and shows a high use of VTE
prophylaxis (two out of every three hospitalised patients).
The adherence to guideline recommendations regarding
indications according to risk level and type of prophylaxis
used was also high. Our results coincide with a French
study, which assessed the adequacy of prophylaxis in sur-
gical patients and compared it with generally accepted
published guidelines [20]. However, our results also sug-
gest that there may be overuse in low-risk patients (12%)
and some underuse in moderate and high-risk patients
(25%). It is interesting to note that most studies point out,
as could be expected, to underutilisation of prophylaxis in
high-risk patients [15,16]; but there are no studies
indicating the problem of overuse. In addition, the adher-
ence was low regarding dose levels and the use of a preop-
erative dose. Similarly, George et al [21] also noticed that
most protocol violations in routine surgical practice con-
sisted of starting subcutaneous heparins postoperatively.
Another finding to be commented on is the variability of
Table 2: Prophylaxis according to number of risk factors of patients
Number of risk factors Patients without prophylaxis n (%) Patients with prophylaxis n (%) Total n (%)
0 18 (82) 4 (18) 22 (100)
1 49 (67) 24 (33) 73 (100)
2 58 (52) 54 (48) 112 (100)
3 27 (30) 62 (70) 89 (100)
4 9 (15.5) 49 (84.5) 58 (100)
≥5 5 (12) 38 (88) 43 (100)
Total 166 (42) 231 (58) 397 (100)
Test for trend p < 0.05.
Table 3: Risk factors of patients and prophylaxis according to risk categories in guidelines
Risk category Low risk Moderate risk High risk Overall Test significance
Number of patients (%) 100 (25) 257 (65) 40 (10) 397 (100)
Mean age (SD) 47.8 (18) 63.2 (15) 67.8 (11) 60 (17) p < 0.001
Mean number risk factors (SD) 1 (0.7) 2.9 (1.2) 4.2 (1) 2.6 (1.4) p < 0.0001
Contra-indications1 n (%) 17 (17) 25 (10) - 42 (11) p < 0.01
Prophylaxis n (%) 11 (11) 184 (72) 36 (90) 231 (58) p < 0.001
Surgical prophylaxis2 n (%) 2 (12) 89 (90) 29 (91) 120 (81) p < 0.0001
Non-surgical prophylaxis3 N (%) 9 (11) 95 (60) 7 (87.5) 111(45) p < 0.0001
1 Contraindications to receive heparins 2 Prophylaxis in patients undergoing surgery 3 Prophylaxis in patients not undergoing surgeryThrombosis Journal 2004, 2 http://www.thrombosisjournal.com/content/2/1/3
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the utilisation of VTE prophylaxis among different wards.
Adherence was particularly high in critical care and sur-
gery wards and lesser in medical wards and emergency
units. A wide variability in the use of VTE prophylaxis
between different wards has already been identified in
other studies [17,20,22-24]. One of the conclusions aris-
ing from these results is that more educational efforts
should be made to improve adherence to all guideline rec-
ommendations and throughout the hospital.
Our main results are similar to other studies in which the
proportion of patients who received effective methods of
prophylaxis also increased after educational interven-
tions, such as guidelines [25,26]. We had previously doc-
umented an underuse of VTE prophylaxis before the
institutional guideline was available [16,19] and an
increased use of VTE prophylaxis two years after its imple-
mentation (unpublished data). A trend towards greater
use of VTE prophylaxis is apparent during a ten-year
period (table 5). Dissemination of guidelines may have
played a role in improving prophylaxis use, but this could
be related to many other factors. In addition, the degree of
improvement with guidelines can be largely influenced by
the methods used in its development, dissemination and
implementation. The guidelines seems to be quite effec-
tive when its development is internal, the dissemination is
undertaken through specific educational intervention and
the implementation is via patient-specific reminder at the
time of consultation [27,28]. Thus, for instance, the pub-
lication of the Fourth ACCP Consensus Conference on
Antithrombotic Therapy [12] alone was insufficient to
change routine practice in prevention of VTE in a study
that included several American hospitals [23]. In contrast,
in a study performed in various short-stay hospitals a for-
mal continuing medical education program significantly
increased the frequency of prophylaxis for VTE [25]. How-
ever, even after those interventions, prophylaxis for VTE
remained underutilised, suggesting that other types of
interventions should be developed [25]. In addition to
this, other factors may also be related to increasing use of
prophylaxis, because this has been observed even in con-
trol groups in hospitals without any guideline implemen-
tation [25]. One of these factors may be the introduction
of new drugs and their promotion by pharmaceutical
companies. Specifically in the field of VTE prophylaxis, at
the beginning of the nineties, a new type of heparins, frac-
tionated heparin or LMWH, was introduced. So, varia-
tions in thromboprophylaxis may be due to different
factors such as the clinical guideline implementation, the
introduction and promotion of LMWH, as well as general
awareness among physicians over time.
Table 4: Risk factors of patients and prophylaxis of venous thrombosis according to different wards
Ward Medicine Surgery Critical care Emergency Overall Test 
significance
Number of patients 166 155 44 32 397
Mean age (sd) 60 (17) 59 (17) 52 (18) 71 (16) 60 (17) p < 0.05
Mean number risk factors (sd) 2.2 (1.3) 2.6 (1.3) 3.9 (1.8) 2.6 (1.3) 2.6 (1.4) p < 0.05
Moderate + High-risk patients n (%) 112 (67) 118 (76) 42 (95) 25 (78) 297 (75) p < 0.001
Contrain-dications to heparins n (%) 25 (15) 8 (5) 7 (16) 2 (6) 42 (11) p < 0.05
Prophylaxis all patients n (%) 70 (42) 109 (70) 38 (86) 14 (44) 231 (58) p < 0.001
Prophylaxis Moderate + High-risk patients n (%) 66 (59) 102 (86) 38 (90.5) 14 (56) 220 (74) p < 0.001
Table 5: Trends in venous thromboembolism prophylaxis
Preintervention period Postintervention period
1990 1992a 1997a 1999
Number of patients 615 187 194 397
Mean age (SD) 60 (15.5) 60 (17) 61 (17) 60 (17)
Mean number risk factors (SD) 2.3 (1) 2.6 (1) 2.5 (1) 2.6 (1)
Contrain-dications to heparins n (%) 70 (11) 33 (18) 56 (29) 42 (11)
Prophylaxis in all patients n (%) 82 (13) 73 (39) 103 (53) 231 (58)
Prophylaxis in patients with ≥2 risk factors n/N (%) 79/444 (22) 63/116 (54) 85/110 (77) 201/302 (67)
Prophylaxis in surgical patients n/N (%) 39/183 (21) 49/89 (55) 65/73 (89) 109/155 (70)
a Patients of Internal Medicine and General Surgery Wards.Thrombosis Journal 2004, 2 http://www.thrombosisjournal.com/content/2/1/3
Page 6 of 7
(page number not for citation purposes)
Our study has several important limitations. First of all,
we did not include a control group in order to determine
the real effect of guideline; so, we can not exclude the
effect of confounding factors mentioned above. In
addition, we can not establish the external validity of our
results, because our hospital is a tertiary teaching hospital
with typical and non-typical patients, and with expertise
staff that is non-representative of those throughout the
country.; so we do not know whether these results are sim-
ilar in other hospitals. A key issue is the validity of guide-
line used as a reference of the evidence for assessing the
practice. It has been argued that official guidelines are
hardly ever evidence-based because the input of expert
groups is above minimum and the long delay between
arising new data and guideline completion or updating.
Nevertheless, the guidelines were based on the best possi-
ble evidence, and the main recommendations of guide-
lines, for instance appropriate prophylaxis use in
moderate and high-risk patients, have clearly showed
themselves to be effective [1-10] and efficient [29-32].
Conclusions
Prophylaxis of VTE is generally used in risk patients, but
appropriate adherence to guidelines is less frequent and
variable among different wards. There is room for
improvement and more efforts need to be made in order
to better disseminate and implement the guidelines' rec-
ommendations throughout the hospital and to reduce
variability in daily practice decision making. Appropriate
corrective measures to improve prophylaxis of VTE may
be continuing medical education with discussion and
consensus with physicians, dissemination of guidelines
with relevant information and regular clinical audit as
feedback on prescribing patterns for groups of physicians.
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